ArticleBMC cancer2025
Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAggressive mature B-cell non-Hodgkin lymphoma (B-NHL) is the most common subtype of non-Hodgkin lymphoma in children and adolescents. However, little progress has been made in determining the prognostic factors of children and adolescents with B-NHL. Based on the effect of cytokines in other cancer types, this study explored the effect of cytokines on the prognosis of children and adolescents with B-NHL.
methodsThe levels of serum cytokines including interleukin-2 (IL-2), IL-4, IL-6, IL-10, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) were detected at diagnosis. Correlations between cytokines, clinical characteristics, and treatment outcomes were retrospectively analyzed.
resultsIn total, 139 patients aged < 18 years with newly diagnosed mature B-NHL were enrolled. Patients with elevated IL-6 levels at diagnosis (n = 35) had worse 5-year event-free survival (85.3% vs. 97.1%, p = 0.01) and overall survival (OS) rates (91.2% vs. 99.0%, p = 0.02) than those with normal IL-6 levels. Patients with elevated IL-10 (n = 35) had worse 5-year OS rates (91.4% vs. 99.0%, p = 0.02) than those with normal IL-10 levels. Cox multivariate analysis identified elevated IL-6 levels at diagnosis as an independent adverse prognostic factor in pediatric B-NHL. Elevated IL-6 levels correlated positively with IL-10 levels, and patients with simultaneously elevated IL-6 and IL-10 levels had the worst prognosis in the entire cohort.
conclusionsOur study suggests that elevated serum IL-6 and IL-10 levels at diagnosis are associated with poor prognosis in pediatric mature B-NHL and may have the potential to inform risk stratification. Future prospective, multi-center studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.